New Cross-Species Biomarker Identified for Fragile X Syndrome

A groundbreaking, open-access study published in Nature Communications has successfully identified a non-invasive, objective biomarker for Fragile X syndrome, the most common inherited form of autism. This significant discovery introduces a biomarker shared between human males and male mice, directly addressing a critical challenge in neurological research where potential treatments effective in mice often fail to translate effectively to humans.

The research team, spearheaded by postdoc Sara Kornfeld-Sylla and Picower Professor Mark Bear at MIT, employed electroencephalography (EEG) to measure brain waves. They conducted these measurements in human males and male mice, both with and without the genetic alterations characteristic of Fragile X syndrome. Through a novel analytical approach, the team uncovered specific and robust patterns of differences in low-frequency brain waves between typical and Fragile X brains. These patterns were remarkably consistent across both species and different age ranges.

This non-invasive, objective biomarker for Fragile X syndrome is shared between human males and male mice, offering a crucial bridge in translational neuroscience.

Detailed Biomarker Characteristics

The identified biomarker is rooted in specific alterations of low-frequency brain waves. In adult men and mice with Fragile X syndrome, a distinct peak in the power of low-frequency waves shifts to a significantly slower frequency when compared to their neurotypical counterparts. For boys and juvenile mice affected by Fragile X, a reduced power in the same peak is observed, alongside a similar, though less pronounced, shift to a slower frequency.

Further analysis revealed that this key peak comprises two distinct subpeaks. Crucially, the lower-frequency subpeak specifically correlates with Fragile X syndrome. Subsequent experiments in mice established a connection between this subpeak and the activity of somatostatin-expressing inhibitory neurons, which play a vital role in shaping brain wave patterns.

Promising Indication of Treatment Efficacy

The study yielded compelling evidence that this biomarker can effectively indicate the physiological effects of arbaclofen. Arbaclofen is a candidate treatment for Fragile X syndrome, known for its ability to enhance inhibition within the brain. Fragile X model mice treated with arbaclofen demonstrated a notable increase in the power of the key subpeak, effectively reducing the deficit observed in juvenile mice.

This finding provides a robust proof of concept that the biomarker is sensitive to drug treatments and directly reflects underlying pathophysiology, such as reduced GABA responsiveness in Fragile X syndrome.

Ultimately, this cross-species biomarker offers an invaluable tool to directly compare the physiological effects of drug treatments between mice and humans. This capability holds immense potential to accelerate the development of therapies not only for Fragile X syndrome but also for other complex brain disorders characterized by disruptions in low-frequency brain waves.